Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Kevzara (sarilumab) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions:
This form is used by Kaiser Permanente and/or participating providers for coverage of **Kevzara (sarilumab).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

1 – Patient Information

Patient Name: ______________________________ Kaiser Medical ID#: _________________ Date of Birth: _____________

2 – Prescriber Information

Is the prescriber a rheumatologist, Gastroenterologist or Dermatologist? □ No □ Yes

If consulted with a specialist, specialist name and specialty: ____

Prescriber Name: ______________________________ Specialty: ___________________________NPI: __________________

Prescriber Address: ____

Prescriber Phone #: __________________________Prescriber Fax #: ___________________________

Please check the boxes that apply:
□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: ________________________________ Pharmacy NPI: ____

Pharmacy Phone #_______________________________ Pharmacy Fax #: ____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: ____
Sig: ____

Drug 2: Name/Strength/Formulation: ____
Sig: ____

5– Diagnosis/Clinical Criteria

Initial Therapy:

1. Does the member have diagnosis of rheumatoid arthritis? **AND**
   □ No □ Yes
2. Does the member have intolerance, contraindication to, or failed treatment with at least a 6-week trial of one of the following:
   - Subcutaneous methotrexate, hydroxychloroquine, leflunomide, or sulfasalazine, AND
   - Xeljanz (tofacitinib), AND
   - At least 1 TNF inhibitor (e.g., Humira, Enbrel, Inflectra), AND
   - Actemra (tocilizumab) or Orencia (abatacept)

   □ No □ Yes

   OR
3. Does the member have diagnosis of giant arteritis?
   □ No □ Yes

   OR
4. Does the member have diagnosis of active polyarticular or systemic juvenile idiopathic arthritis? **AND**
   □ No □ Yes
5. The member must not be receiving Kevzara in combination with any of the following:
   - Biologic DMARD (e.g., Enbrel, Humira, Cimzia, Simponi)
   - Janus kinase inhibitor (e.g., Xeljanz, Olumiant)

   □ No □ Yes

Continuation of Therapy:

1. Does the member document a clinically significant benefit from medication? **AND**
   □ No □ Yes
2. Has a specialist follow-up occurred in the last 12 months?
   □ No □ Yes

7 – Prescriber Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration: __________

____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	**Date:**

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility